Merck KGaA Expects Higher Profitability, Sales in 2022 After 1Q Earnings Rise
12 Mayo 2022 - 12:31AM
Noticias Dow Jones
By Xavier Fontdegloria
Merck KGaA said Thursday that it expected higher profit and
sales for 2022 after earnings and revenue increased in the first
quarter driven by a strong performance of its life science
division.
The German pharmaceuticals-and-chemicals company posted an after
tax profit of 884 million euros ($929.5 million) in the first
quarter, up 18% from the EUR748 million registered the same period
a year earlier. Analysts expected Merck KGaA to report an after-tax
profit of EUR1.05 billion, according to a consensus forecast
provided by FactSet.
Net Sales increased 12% to EUR5.20 billion, with organic growth
driven by all its business sectors, the company said. Economists
expected sales to come in at EUR5.09 billion.
Earnings before interest, taxes, depreciation and amortization
before one-time items, or Ebitda pre--one of the company's
closely-watched metrics--rose 7.8% to EUR1.63 billion compared with
EUR1.51 billion the prior year.
Merck KGaA said net sales for 2022 are expected at between
EUR21.6 billion and EUR22.8 billion compared with EUR19.69 billion
in 2021, while Ebitda pre is seen coming in between EUR6.6 billion
and EUR7.1 billion from EUR6.10 billion.
However, the forecast is subject to increased uncertainty and is
based on the assumption of short and locally restricted lockdowns
in China, the company said.
Write to Xavier Fontdegloria at xavier.fontdegloria@wsj.com
(END) Dow Jones Newswires
May 12, 2022 01:16 ET (05:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Merck KGaA (PK) (USOTC:MKKGY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Merck KGaA (PK) (OTCMarkets): 0 recent articles
Más de Merck KGaA (PK) Artículos de Noticias